These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10770744)

  • 1. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
    Zinner SH; Gilbert D; Dudley MN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
    Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
    Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
    Schick DG; Canawati HN; Montgomerie JZ
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.
    Lamp KC; Vickers MK
    Antimicrob Agents Chemother; 1998 Feb; 42(2):231-5. PubMed ID: 9527765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of sulbactam/ampicillin and ampicillin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Fabbri A; Tacchella A; Belli ML; Losurdo G
    Chemioterapia; 1988 Oct; 7(5):306-8. PubMed ID: 3224398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots.
    Palmer SM; Rybak MJ
    J Antimicrob Chemother; 1997 Apr; 39(4):515-8. PubMed ID: 9145825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.
    Backo M; Gaenger E; Burkart A; Chai YL; Bayer AS
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2565-8. PubMed ID: 10508047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits.
    Chambers HF; Kartalija M; Sande M
    J Infect Dis; 1995 Apr; 171(4):897-902. PubMed ID: 7706817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative in vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antibiotics with respect to staphylococci and pneumococci].
    Sidorenko SV; Rezvan SP; Speranskaia ON; Tikhonova As; Navashin SM; Ansolis LE; Tsvigun EA; Kuleshov SE; Budanov SV
    Antibiot Khimioter; 1995 Mar; 40(3):22-7. PubMed ID: 7575010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Cohen MA; Huband MD
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus.
    Giamarellou-Bourboulis EJ; Sambatakou H; Grecka P; Chryssouli Z; Giamarellou H
    Diagn Microbiol Infect Dis; 1999 Aug; 34(4):301-7. PubMed ID: 10459481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.